Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

By sjmartinez • September 27, 2024

Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Tuchayi AM, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816. Epub ahead of print. PMID: 39327018.

Tags: Cardiology/Epi, EAP, General Internal Medicine, mCRPC, PSMA PET, Publications, vision

Related Posts

The Cardiovascular Care of the Pediatric Athlete

Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure with Reduced Ejection Fraction in a Safety-Net Healthcare System

DeJong C, Durstenfeld MS, Davis J, Wang CS, Chen J, Kazi DS, Hickey MD, Grochowski J, Steward WT, Riley ED, Zier LS, Moreau N, Huffman[...]